I am a passionate healthcare and pharmaceutical strategist with proven experience creating “value from vision”. I have more than 28 years of pharmaceutical industry experience, the majority as a new product strategy and business development professional.

I am currently Executive Director, Head of Alliance & Integration Team for Alexion, AstraZeneca Rare Disease. My team is part of Alexion’s Business Development team. AIT strategically manages Alexion’s integrations, licenses, partnerships, and collaborations.  As the key liaison between Alexion and the business development partner, AIT ensures that the Alexion achieves maximum value from each transaction.

Prior to joining Alexion, I held several roles as a member of the Pfizer Inc. Commercial organisation.  Specifically, I was the New Products Commercial lead for three currently marketed products including a treatment for lung and breast cancer, rheumatoid arthritis, and an anticoagulant.  I received an AB degree in Biochemistry from Smith College (Northampton, MA), an MBA in Strategic Planning & Accounting from the Katz Graduate School of Business, University of Pittsburgh, and an Executive MBA Certificate in Strategic Finance from the Harvard Business School.


Our goal as pharmaceutical professionals is to translate innovative science into meaningful medicines. This doesn’t happen by accident. We achieve this goal by actively listening to patients and all our stakeholders to uncover how we can best meet their needs and expectations. This is what inspires me and what gets me up in the morning, every single workday. Actively partnering with and listening to key external stakeholders is how we deliver for patients.

Judy Campagnari Executive Director, Head of Global Patient Insights & Solutions

2023

AstraZeneca Women as Leaders (WAL) Program Valedictorian

2022

Women of Color in Pharma - Trailblazer Award

2021

Alexion Excellence Award

CURRENT ROLE

Executive Director, Head of Alliance and Integration Team (Strategy and Business Development Team, Alexion)

2014 - 2020

Joined Alexion to create the New Product Strategy Team; Head of New Product Strategy; Head of Business Development Commercial Team; Commercial Lead for numerous business development transactions including Wilson Therapeutics, Syntimmune, Achillion, and Caelum Biosciences, Alexion

2017

Named on two patents for use of modified mRNA in treatment of two rare diseases (propionic acidemia and progressive familial intrahepatic cholestasis)

2010 - 2013

Director/Team Leader, Global Business Development – Commercial, Pfizer; Led BD Commercial Team for Pfizer Primary Care business unit; Business Development Commercial lead for successful Pfizer-BMS anticoagulant therapy co-promote transaction

Veeva ID: Z4-62680
Date of preparation: March 2024